Karen Hsiao Ashe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Karen Hsiao Ashe has a total of 157 co-authors. Here are the top co-authors by number of shared publications:
- Peng Liu
University of Minnesota 2101 6th Street SE
7 shared publications Lisa J. Kemper
N. Bud Grossman Center for Memory Research and Care, Minneapolis, MN 55455, USA
6 shared publicationsKailee Leinonen-Wright
Affiliations N. Bud Grossman Center for Memory Research and Care, University of Minnesota, Minneapolis, MN, United States of America, Department of Neurology, University of Minnesota, Minneapolis, MN, United States of America
5 shared publicationsKathleen R. Zahs
Department of Neurology, University of Minnesota, Minneapolis, MN 55455, USA; N. Bud Grossman Center for Memory Research and Care, University of Minnesota, Minneapolis, MN 55455, USA
5 shared publicationsPeng Liu
N. Bud Grossman Center for Memory Research and Care
5 shared publicationsColleen Forster
BLS Histology and IHC Laboratory, Minneapolis, MN, USA
4 shared publications
Latest Publications
- Open Access
Aβ*56 is present in brain extracts enriched for extracellular proteins
Amyloid-β (Aβ) oligomers are believed to be important in the pathogenesis of Alzheimer’s disease (AD). Aβ*56 is an Aβ oligomer that has been reported in several lines of transgenic mice modeling AD, including Tg2576, hAPP-J20, 3xTgAD, 5xFAD, and APPTTA. In Tg2576 mice, Aβ*56 appears several months before neuritic plaques and impairs memory when injected into the brains of healthy rodents. Aβ*56 has several distinctive biochemical features: 1) it is soluble in aqueous buffers, 2) it is stable in the ionic detergent sodium dodecyl sulfate (SDS), 3) it has an apparent mass of 56 kDa whether measured by denaturing SDS polyacrylamide gel electrophoresis or non-denaturing size-exclusion chromatography, 4) it binds to A11 conformational antibodies that recognize non-fibrillar oligomeric assemblies, and 5) it contains canonical Aβ(1-40) and/or Aβ(1-42). Here, we show its presence in Tg2576 brain extracts enriched for extracellular proteins and conclude that Aβ*56 is present in the extracellular space.
Open AccessAβ*56 is present in brain extracts enriched for extracellular proteins
Amyloid-β (Aβ) oligomers are believed to be important in the pathogenesis of Alzheimer’s disease (AD). Aβ*56 is an Aβ oligomer that has been reported in several lines of transgenic mice modeling AD, including Tg2576, hAPP-J20, 3xTgAD, 5xFAD, and APPTTA. In Tg2576 mice, Aβ*56 appears several months before neuritic plaques and impairs memory when injected into the brains of healthy rodents. Aβ*56 has several distinctive biochemical features: 1) it is soluble in aqueous buffers, 2) it is stable in the ionic detergent sodium dodecyl sulfate (SDS), 3) it has an apparent mass of 56 kDa whether measured by denaturing SDS polyacrylamide gel electrophoresis or non-denaturing size-exclusion chromatography, 4) it binds to A11 conformational antibodies that recognize non-fibrillar oligomeric assemblies, and 5) it contains canonical Aβ(1-40) and/or Aβ(1-42). Here, we show its presence in Tg2576 brain extracts enriched for extracellular proteins and conclude that Aβ*56 is present in the extracellular space.
- RetractionOpen Access
- 24 June 2024
- Published by Springer Nature in Nature
- Vol. 631 (8019) , 240
Retraction Note: A specific amyloid-β protein assembly in the brain impairs memory
- 24 June 2024
- Published by Springer Nature in Nature
- Vol. 631 (8019) , 240
RetractionOpen AccessRetraction Note: A specific amyloid-β protein assembly in the brain impairs memory
- Open Access
Aβ*56 is a stable oligomer that correlates with age-related memory loss in Tg2576 mice
Summary: Amyloid-β (Aβ) oligomers consist of fibrillar and non-fibrillar soluble assemblies of the Aβ peptide. Tg2576 human amyloid precursor protein (APP)-expressing transgenic mice modeling Alzheimer’s disease produce Aβ*56, a non-fibrillar Aβ assembly that has been shown by several groups to relate more closely to memory deficits than plaques. Previous studies did not decipher specific forms of Aβ present in Aβ*56. Here, we confirm and extend the biochemical characterization of Aβ*56. We used anti-Aβ(1-x), anti-Aβ(x-40), and A11 anti-oligomer antibodies in conjunction with western blotting, immunoaffinity purification, and size-exclusion chromatography to probe aqueous brain extracts from Tg2576 mice of different ages. We found that Aβ*56 is a ∼56-kDa, SDS-stable, A11-reactive, non-plaque-related, water-soluble, brain-derived oligomer containing canonical Aβ(1-40) that correlates with age-related memory loss. The unusual stability of this high molecular-weight oligomer renders it an attractive candidate for studying relationships between molecular structure and effects on brain function.
Open AccessAβ*56 is a stable oligomer that correlates with age-related memory loss in Tg2576 mice
Summary: Amyloid-β (Aβ) oligomers consist of fibrillar and non-fibrillar soluble assemblies of the Aβ peptide. Tg2576 human amyloid precursor protein (APP)-expressing transgenic mice modeling Alzheimer’s disease produce Aβ*56, a non-fibrillar Aβ assembly that has been shown by several groups to relate more closely to memory deficits than plaques. Previous studies did not decipher specific forms of Aβ present in Aβ*56. Here, we confirm and extend the biochemical characterization of Aβ*56. We used anti-Aβ(1-x), anti-Aβ(x-40), and A11 anti-oligomer antibodies in conjunction with western blotting, immunoaffinity purification, and size-exclusion chromatography to probe aqueous brain extracts from Tg2576 mice of different ages. We found that Aβ*56 is a ∼56-kDa, SDS-stable, A11-reactive, non-plaque-related, water-soluble, brain-derived oligomer containing canonical Aβ(1-40) that correlates with age-related memory loss. The unusual stability of this high molecular-weight oligomer renders it an attractive candidate for studying relationships between molecular structure and effects on brain function.
- Open Access
- 21 September 2022
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (9) , e0274784
Caspase-2 mRNA levels are not elevated in mild cognitive impairment, Alzheimer’s disease, Huntington’s disease, or Lewy Body dementia
Caspase-2 is a member of the caspase family that exhibits both apoptotic and non-apoptotic properties, and has been shown to mediate synaptic deficits in models of several neurological conditions, including Alzheimer’s disease (AD), Huntington’s disease (HD), and Lewy Body dementia (LBD). Our lab previously reported that caspase-2 protein levels are elevated in these diseases, leading us to hypothesize that elevated caspase-2 protein levels are due to increased transcription of caspase-2 mRNA. There are two major isoforms of caspase-2 mRNA, caspase-2L and caspase-2S. We tested our hypothesis by measuring the levels of these mRNA isoforms normalized to levels of RPL13 mRNA, a reference gene that showed no disease-associated changes. Here, we report no increases in caspase-2L mRNA levels in any of the three diseases studied, AD (with mild cognitive impairment (MCI)), HD and LBD, disproving our hypothesis. Caspase-2S mRNA showed a non-significant downward trend in AD. We also analyzed expression levels of SNAP25 and βIII-tubulin mRNA. SNAP25 mRNA was significantly lower in AD and there were downward trends in MCI, LBD, and HD. βIII-tubulin mRNA expression remained unchanged between disease groups and controls. These findings indicate that factors besides transcriptional regulation cause increases in caspase-2 protein levels. The reduction of SNAP25 mRNA expression suggests that presynaptic dysfunction contributes to cognitive deficits in neurodegeneration.
- 21 September 2022
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (9) , e0274784
Open AccessCaspase-2 mRNA levels are not elevated in mild cognitive impairment, Alzheimer’s disease, Huntington’s disease, or Lewy Body dementia
Caspase-2 is a member of the caspase family that exhibits both apoptotic and non-apoptotic properties, and has been shown to mediate synaptic deficits in models of several neurological conditions, including Alzheimer’s disease (AD), Huntington’s disease (HD), and Lewy Body dementia (LBD). Our lab previously reported that caspase-2 protein levels are elevated in these diseases, leading us to hypothesize that elevated caspase-2 protein levels are due to increased transcription of caspase-2 mRNA. There are two major isoforms of caspase-2 mRNA, caspase-2L and caspase-2S. We tested our hypothesis by measuring the levels of these mRNA isoforms normalized to levels of RPL13 mRNA, a reference gene that showed no disease-associated changes. Here, we report no increases in caspase-2L mRNA levels in any of the three diseases studied, AD (with mild cognitive impairment (MCI)), HD and LBD, disproving our hypothesis. Caspase-2S mRNA showed a non-significant downward trend in AD. We also analyzed expression levels of SNAP25 and βIII-tubulin mRNA. SNAP25 mRNA was significantly lower in AD and there were downward trends in MCI, LBD, and HD. βIII-tubulin mRNA expression remained unchanged between disease groups and controls. These findings indicate that factors besides transcriptional regulation cause increases in caspase-2 protein levels. The reduction of SNAP25 mRNA expression suggests that presynaptic dysfunction contributes to cognitive deficits in neurodegeneration.
- 26 August 2022
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 377 (6609) , 935
Alzheimer’s target still viable but untested
- 26 August 2022
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 377 (6609) , 935
Alzheimer’s target still viable but untested
- Open Access
- 25 January 2021
- Published by Wolters Kluwer Health in Neural Regeneration Research
- Vol. 16 (9) , 1774-1775
The molecular implications of a caspase-2-mediated site-specific tau cleavage in tauopathies
Neural Regen Res, Official publication of Publishing House of Neural Regeneration Research China Association of Rehabilitation Medicine,China
- 25 January 2021
- Published by Wolters Kluwer Health in Neural Regeneration Research
- Vol. 16 (9) , 1774-1775
Open AccessThe molecular implications of a caspase-2-mediated site-specific tau cleavage in tauopathies
Neural Regen Res, Official publication of Publishing House of Neural Regeneration Research China Association of Rehabilitation Medicine,China
- Open Access
- 16 June 2020
- Published by Wiley in Alzheimer's & Dementia
- Vol. 16 (11) , 1561-1567
The biogenesis and biology of amyloid β oligomers in the brain
The repeated failure of clinical trials targeting the amyloid beta (Aβ) protein has challenged the amyloid cascade hypothesis. In this perspective, I discuss the biogenesis and biology of Aβ, from the arrangement of its atoms to its effects on the human brain. I hope that this analysis will help guide future attempts to home in on this elusive therapeutic target.
- 16 June 2020
- Published by Wiley in Alzheimer's & Dementia
- Vol. 16 (11) , 1561-1567
Open AccessThe biogenesis and biology of amyloid β oligomers in the brain
The repeated failure of clinical trials targeting the amyloid beta (Aβ) protein has challenged the amyloid cascade hypothesis. In this perspective, I discuss the biogenesis and biology of Aβ, from the arrangement of its atoms to its effects on the human brain. I hope that this analysis will help guide future attempts to home in on this elusive therapeutic target.
- Open Access
- 12 May 2020
- Published by Springer Nature in Scientific Reports
- Vol. 10 (1) , 1
Author Correction: A soluble truncated tau species related to cognitive dysfunction is elevated in the brain of cognitively impaired human individuals
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
- 12 May 2020
- Published by Springer Nature in Scientific Reports
- Vol. 10 (1) , 1
Open AccessAuthor Correction: A soluble truncated tau species related to cognitive dysfunction is elevated in the brain of cognitively impaired human individuals
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
- Open Access
- 2 March 2020
- Published by Springer Nature in Scientific Reports
- Vol. 10 (1) , 1-18
A soluble truncated tau species related to cognitive dysfunction is elevated in the brain of cognitively impaired human individuals
Neurofibrillary tangles are a pathological hallmark of Alzheimer’s disease, and their levels correlate with the severity of cognitive dysfunction in humans. However, experimental evidence suggests that soluble tau species cause cognitive deficits and memory impairment. Our recent study suggests that caspase-2 (Casp2)-catalyzed tau cleavage at aspartate 314 mediates synaptic dysfunction and memory impairment in mouse and cellular models of neurodegenerative disorders. Δtau314, the C-terminally-truncated cleavage products, are soluble and present in human brain. In addition, levels of Δtau314 proteins are elevated in the brain of the cognitively impaired individuals compared to the cognitively normal individuals, indicating a possible role for Δtau314 proteins in cognitive deterioration. Here we show that (1) Δtau314 proteins are present in the inferior temporal gyrus of human brains; (2) Δtau314 proteins are generated from all six tau splicing isoforms, (3) levels of both Casp2 and Δtau314 proteins are elevated in cognitively impaired individuals compared to cognitively normal individuals, and (4) levels of Δtau314 proteins show a modest predictive value for dementia. These findings advance our understanding of the characteristics of Δtau314 proteins and their relevance to cognitive dysfunction and shed light on the contribution of Casp2-mediated Δtau314 production to cognitive deterioration.
- 2 March 2020
- Published by Springer Nature in Scientific Reports
- Vol. 10 (1) , 1-18
Open AccessA soluble truncated tau species related to cognitive dysfunction is elevated in the brain of cognitively impaired human individuals
Neurofibrillary tangles are a pathological hallmark of Alzheimer’s disease, and their levels correlate with the severity of cognitive dysfunction in humans. However, experimental evidence suggests that soluble tau species cause cognitive deficits and memory impairment. Our recent study suggests that caspase-2 (Casp2)-catalyzed tau cleavage at aspartate 314 mediates synaptic dysfunction and memory impairment in mouse and cellular models of neurodegenerative disorders. Δtau314, the C-terminally-truncated cleavage products, are soluble and present in human brain. In addition, levels of Δtau314 proteins are elevated in the brain of the cognitively impaired individuals compared to the cognitively normal individuals, indicating a possible role for Δtau314 proteins in cognitive deterioration. Here we show that (1) Δtau314 proteins are present in the inferior temporal gyrus of human brains; (2) Δtau314 proteins are generated from all six tau splicing isoforms, (3) levels of both Casp2 and Δtau314 proteins are elevated in cognitively impaired individuals compared to cognitively normal individuals, and (4) levels of Δtau314 proteins show a modest predictive value for dementia. These findings advance our understanding of the characteristics of Δtau314 proteins and their relevance to cognitive dysfunction and shed light on the contribution of Casp2-mediated Δtau314 production to cognitive deterioration.